BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007;129:957-968. [PMID: 17540175 DOI: 10.1016/j.cell.2007.03.051] [Cited by in Crossref: 426] [Cited by in F6Publishing: 397] [Article Influence: 28.4] [Reference Citation Analysis]
Number Citing Articles
1 Porat-Shliom N, Kloog Y, Donaldson JG. A unique platform for H-Ras signaling involving clathrin-independent endocytosis. Mol Biol Cell 2008;19:765-75. [PMID: 18094044 DOI: 10.1091/mbc.e07-08-0841] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
2 Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009;13:339-62. [PMID: 19236156 DOI: 10.1517/14712590902735795] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
3 Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. APMIS 2013;121:954-66. [DOI: 10.1111/apm.12152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
4 Nussinov R, Wang G, Tsai CJ, Jang H, Lu S, Banerjee A, Zhang J, Gaponenko V. Calmodulin and PI3K Signaling in KRAS Cancers. Trends Cancer 2017;3:214-24. [PMID: 28462395 DOI: 10.1016/j.trecan.2017.01.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
5 Daaboul HE, Daher CF, Bodman-smith K, Taleb RI, Shebaby WN, Boulos J, Dagher C, Mroueh MA, El-sibai M. Antitumor activity of β-2-himachalen-6-ol in colon cancer is mediated through its inhibition of the PI3K and MAPK pathways. Chemico-Biological Interactions 2017;275:162-70. [DOI: 10.1016/j.cbi.2017.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
6 Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725-737. [PMID: 31564718 DOI: 10.1038/s41416-019-0573-8] [Cited by in Crossref: 167] [Cited by in F6Publishing: 174] [Article Influence: 55.7] [Reference Citation Analysis]
7 Nieto-Sampedro M, Valle-Argos B, Gómez-Nicola D, Fernández-Mayoralas A, Nieto-Díaz M. Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. Clin Med Insights Oncol. 2011;5:265-314. [PMID: 22084619 DOI: 10.4137/cmo.s7685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
8 Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol 2011;13:39-51. [PMID: 22189424 DOI: 10.1038/nrm3255] [Cited by in Crossref: 355] [Cited by in F6Publishing: 324] [Article Influence: 32.3] [Reference Citation Analysis]
9 Berndtsson M, Hernlund E, Shoshan MC, Linder S. Conditional drug screening shows that mitotic inhibitors induce AKT/PKB-insensitive apoptosis. J Chem Biol 2009;2:81-7. [PMID: 19568785 DOI: 10.1007/s12154-009-0017-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Michael JV, Wurtzel JG, Goldfinger LE. Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains. Oncogenesis. 2016;5:e228. [PMID: 27239960 DOI: 10.1038/oncsis.2016.36] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhang M, Jang H, Gaponenko V, Nussinov R. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains. Biophys J 2017;113:1956-67. [PMID: 29117520 DOI: 10.1016/j.bpj.2017.09.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
12 Haeussler DJ, Pimentel DR, Hou X, Burgoyne JR, Cohen RA, Bachschmid MM. Endomembrane H-Ras controls vascular endothelial growth factor-induced nitric-oxide synthase-mediated endothelial cell migration. J Biol Chem 2013;288:15380-9. [PMID: 23548900 DOI: 10.1074/jbc.M112.427765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cooley R, Kara N, Hui NS, Tart J, Roustan C, George R, Hancock DC, Binkowski BF, Wood KV, Ismail M, Downward J. Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets. Wellcome Open Res 2020;5:20. [PMID: 32587898 DOI: 10.12688/wellcomeopenres.15675.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Qu X, Zhou B, Scott Baldwin H. Tie1 is required for lymphatic valve and collecting vessel development. Dev Biol 2015;399:117-28. [PMID: 25576926 DOI: 10.1016/j.ydbio.2014.12.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
15 Anderson JL, Park A, Akiyama R, Tap WD, Denny CT, Federman N. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. PLoS One 2015;10:e0133610. [PMID: 26402468 DOI: 10.1371/journal.pone.0133610] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
16 Beltran L, Chaussade C, Vanhaesebroeck B, Cutillas PR. Calpain interacts with class IA phosphoinositide 3-kinases regulating their stability and signaling activity. Proc Natl Acad Sci U S A 2011;108:16217-22. [PMID: 21930956 DOI: 10.1073/pnas.1107692108] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
17 Stephens L, Hawkins P. Signalling via class IA PI3Ks. Adv Enzyme Regul 2011;51:27-36. [PMID: 21035483 DOI: 10.1016/j.advenzreg.2010.09.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
18 Carnero A, Paramio JM. The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol 2014;4:252. [PMID: 25295225 DOI: 10.3389/fonc.2014.00252] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 11.9] [Reference Citation Analysis]
19 Castillo SD, Baselga E, Graupera M. PIK3CA mutations in vascular malformations: . Current Opinion in Hematology 2019;26:170-8. [DOI: 10.1097/moh.0000000000000496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
20 Hintelmann K, Kriegs M, Rothkamm K, Rieckmann T. Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting. Front Oncol 2020;10:1260. [PMID: 32903756 DOI: 10.3389/fonc.2020.01260] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. PLoS One 2018;13:e0193849. [PMID: 29799846 DOI: 10.1371/journal.pone.0193849] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
22 Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J Neurosci 2008;28:7847-62. [PMID: 18667617 DOI: 10.1523/JNEUROSCI.1496-08.2008] [Cited by in Crossref: 111] [Cited by in F6Publishing: 82] [Article Influence: 7.9] [Reference Citation Analysis]
23 Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 2021;35:787-820. [PMID: 34074695 DOI: 10.1101/gad.348226.120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Chen YT, Tan KA, Pang LY, Argyle DJ. The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention. BMC Vet Res 2012;8:73. [PMID: 22647622 DOI: 10.1186/1746-6148-8-73] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
25 Kern F, Niault T, Baccarini M. Ras and Raf pathways in epidermis development and carcinogenesis. Br J Cancer 2011;104:229-34. [PMID: 21081934 DOI: 10.1038/sj.bjc.6606009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
26 Suire S, Lécureuil C, Anderson KE, Damoulakis G, Niewczas I, Davidson K, Guillou H, Pan D, Jonathan Clark, Phillip T Hawkins, Stephens L. GPCR activation of Ras and PI3Kc in neutrophils depends on PLCb2/b3 and the RasGEF RasGRP4. EMBO J 2012;31:3118-29. [PMID: 22728827 DOI: 10.1038/emboj.2012.167] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
27 Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis. 2013;18:509-520. [PMID: 23371322 DOI: 10.1007/s10495-013-0807-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
28 Ehrenreiter K, Kern F, Velamoor V, Meissl K, Galabova-kovacs G, Sibilia M, Baccarini M. Raf-1 Addiction in Ras-Induced Skin Carcinogenesis. Cancer Cell 2009;16:149-60. [DOI: 10.1016/j.ccr.2009.06.008] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 5.4] [Reference Citation Analysis]
29 Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 2014;111:6395-400. [PMID: 24737887 DOI: 10.1073/pnas.1323004111] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
30 Berzat A, Hall A. Cellular responses to extracellular guidance cues. EMBO J 2010;29:2734-45. [PMID: 20717143 DOI: 10.1038/emboj.2010.170] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 6.1] [Reference Citation Analysis]
31 Goldfinger LE. Choose your own path: specificity in Ras GTPase signaling. Mol Biosyst. 2008;4:293-299. [PMID: 18354782 DOI: 10.1039/b716887j] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
32 Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11:329-341. [PMID: 20379207 DOI: 10.1038/nrm2882] [Cited by in Crossref: 1057] [Cited by in F6Publishing: 1034] [Article Influence: 88.1] [Reference Citation Analysis]
33 Ilić N, Roberts TM. Comparing the roles of the p110α and p110β isoforms of PI3K in signaling and cancer. Curr Top Microbiol Immunol 2010;347:55-77. [PMID: 20517719 DOI: 10.1007/82_2010_63] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
34 Li X, Dai J, Ni D, He X, Zhang H, Zhang J, Fu Q, Liu Y, Lu S. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B. Int J Biol Macromol 2020;144:643-55. [PMID: 31816384 DOI: 10.1016/j.ijbiomac.2019.12.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
35 Daaboul HE, Dagher C, Taleb RI, Bodman-smith K, Shebaby WN, El-sibai M, Mroueh MA, Daher CF. The chemotherapeutic effect of β-2-himachalen-6-ol in chemically induced skin tumorigenesis. Biomedicine & Pharmacotherapy 2018;103:443-52. [DOI: 10.1016/j.biopha.2018.04.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
36 Yun S, Jung KH, Lee H, Son MK, Seo J, Yan HH, Park BH, Hong S, Hong S. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. Cancer Letters 2013;331:250-61. [DOI: 10.1016/j.canlet.2013.01.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
37 Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009;21:199-208. [PMID: 19200708 DOI: 10.1016/j.ceb.2008.12.007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
38 Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov 2016;6:1090-105. [PMID: 27655435 DOI: 10.1158/2159-8290.CD-16-0716] [Cited by in Crossref: 138] [Cited by in F6Publishing: 78] [Article Influence: 23.0] [Reference Citation Analysis]
39 Williams TD, Peak-Chew SY, Paschke P, Kay RR. Akt and SGK protein kinases are required for efficient feeding by macropinocytosis. J Cell Sci 2019;132:jcs224998. [PMID: 30617109 DOI: 10.1242/jcs.224998] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
40 Ebi H, Faber AC, Engelman JA, Yano S. Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci 2014;105:499-505. [PMID: 24612015 DOI: 10.1111/cas.12383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
41 Toulany M, Minjgee M, Saki M, Holler M, Meier F, Eicheler W, Rodemann HP. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol Ther 2014;15:317-28. [PMID: 24351425 DOI: 10.4161/cbt.27311] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
42 Lau KS, Zhang T, Kendall KR, Lauffenburger D, Gray NS, Haigis KM. BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PLoS One 2012;7:e41343. [PMID: 22815993 DOI: 10.1371/journal.pone.0041343] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
43 Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510. [PMID: 18794884 DOI: 10.1038/onc.2008.245] [Cited by in Crossref: 1239] [Cited by in F6Publishing: 1173] [Article Influence: 88.5] [Reference Citation Analysis]
44 Stephens L, Milne L, Hawkins P. Moving towards a better understanding of chemotaxis. Curr Biol. 2008;18:R485-R494. [PMID: 18522824 DOI: 10.1016/j.cub.2008.04.048] [Cited by in Crossref: 124] [Cited by in F6Publishing: 122] [Article Influence: 8.9] [Reference Citation Analysis]
45 Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010;285:14980-9. [PMID: 20231295 DOI: 10.1074/jbc.M109.085696] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
46 Martinez NG, Thieker DF, Carey LM, Rasquinha JA, Kistler SK, Kuhlman BA, Campbell SL. Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ. J Mol Biol 2021;433:166838. [PMID: 33539876 DOI: 10.1016/j.jmb.2021.166838] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2012;17:205-16. [PMID: 22865098 DOI: 10.1007/s10911-012-9264-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
48 Ma X, Kumar M, Choudhury SN, Becker Buscaglia LE, Barker JR, Kanakamedala K, Liu MF, Li Y. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci U S A 2011;108:10144-9. [PMID: 21646541 DOI: 10.1073/pnas.1103735108] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 14.5] [Reference Citation Analysis]
49 Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss. Elife 2016;5:e17635. [PMID: 27700986 DOI: 10.7554/eLife.17635] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
50 Sun M, Hart JR, Hillmann P, Gymnopoulos M, Vogt PK. Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle 2011;10:3731-9. [PMID: 22045127 DOI: 10.4161/cc.10.21.17920] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
51 Norrmén C, Tammela T, Petrova TV, Alitalo K. Biological Basis of Therapeutic Lymphangiogenesis. Circulation 2011;123:1335-51. [DOI: 10.1161/circulationaha.107.704098] [Cited by in Crossref: 99] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
52 Campa CC, Franco I, Hirsch E. PI3K-C2α: One enzyme for two products coupling vesicle trafficking and signal transduction. FEBS Letters 2015;589:1552-8. [DOI: 10.1016/j.febslet.2015.05.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
53 Demoulin J, Essaghir A. PDGF receptor signaling networks in normal and cancer cells. Cytokine & Growth Factor Reviews 2014;25:273-83. [DOI: 10.1016/j.cytogfr.2014.03.003] [Cited by in Crossref: 143] [Cited by in F6Publishing: 132] [Article Influence: 17.9] [Reference Citation Analysis]
54 Murillo MM, Rana S, Spencer-Dene B, Nye E, Stamp G, Downward J. Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer. Cell Rep 2018;25:3545-3553.e2. [PMID: 30590030 DOI: 10.1016/j.celrep.2018.12.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
55 Vadas O, Burke JE, Zhang X, Berndt A, Williams RL. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal. 2011;4:re2. [PMID: 22009150 DOI: 10.1126/scisignal.2002165] [Cited by in Crossref: 193] [Cited by in F6Publishing: 159] [Article Influence: 17.5] [Reference Citation Analysis]
56 Lu C, Lin L, Tan H, Wu H, Sherman SL, Gao F, Jin P, Chen D. Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice. Hum Mol Genet 2012;21:5039-47. [PMID: 22914733 DOI: 10.1093/hmg/dds348] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
57 Tsun ZY, Possemato R. Amino acid management in cancer. Semin Cell Dev Biol 2015;43:22-32. [PMID: 26277542 DOI: 10.1016/j.semcdb.2015.08.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 8.1] [Reference Citation Analysis]
58 Rajeeve V, Pearce W, Cascante M, Vanhaesebroeck B, Cutillas P. Polyamine production is downstream and upstream of oncogenic PI3K signalling and contributes to tumour cell growth. Biochemical Journal 2013;450:619-28. [DOI: 10.1042/bj20121525] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Konishi T, Yoshidome H, Shida T, Furukawa K, Takayashiki T, Kuboki S, Takano S, Miyazaki M, Ohtsuka M. Phosphorylated mTOR expression as a predictor of survival after liver resection for colorectal liver metastases. J Surg Oncol 2021;124:598-606. [PMID: 34061356 DOI: 10.1002/jso.26551] [Reference Citation Analysis]
60 Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1:170-85. [PMID: 21984976 DOI: 10.1158/2159-8290.CD-11-0039] [Cited by in Crossref: 300] [Cited by in F6Publishing: 185] [Article Influence: 27.3] [Reference Citation Analysis]
61 Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140-156. [PMID: 24481312 DOI: 10.1038/nrd4204] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 954] [Article Influence: 128.3] [Reference Citation Analysis]
62 Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov 2011;1:128-36. [PMID: 22043453 DOI: 10.1158/2159-8290.CD-10-0044] [Cited by in Crossref: 94] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
63 Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13:828-851. [PMID: 25323927 DOI: 10.1038/nrd4389] [Cited by in Crossref: 945] [Cited by in F6Publishing: 853] [Article Influence: 118.1] [Reference Citation Analysis]
64 Safari R, Meuwissen R. Practical Use of Advanced Mouse Models for Lung Cancer. In: Eferl R, Casanova E, editors. Mouse Models of Cancer. New York: Springer; 2015. pp. 93-124. [DOI: 10.1007/978-1-4939-2297-0_5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
65 Denley A, Kang S, Karst U, Vogt PK. Oncogenic signaling of class I PI3K isoforms. Oncogene 2008;27:2561-74. [PMID: 17998941 DOI: 10.1038/sj.onc.1210918] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 4.9] [Reference Citation Analysis]
66 Rhett JM, Khan I, O'Bryan JP. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res 2020;148:69-146. [PMID: 32723567 DOI: 10.1016/bs.acr.2020.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
67 Fernandes MS, Sanches JM, Seruca R. Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. Adv Exp Med Biol 2018;1110:35-53. [PMID: 30623365 DOI: 10.1007/978-3-030-02771-1_4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
68 Chang H, Cai Z, Roberts TM. The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules 2019;9:E713. [PMID: 31703360 DOI: 10.3390/biom9110713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
69 Smith MD, Gong D, Sudhahar CG, Reno JC, Stahelin RV, Best MD. Synthesis and convenient functionalization of azide-labeled diacylglycerol analogues for modular access to biologically active lipid probes. Bioconjug Chem 2008;19:1855-63. [PMID: 18683963 DOI: 10.1021/bc8001002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
70 Baker NM, Yee Chow H, Chernoff J, Der CJ. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin Cancer Res 2014;20:4740-6. [PMID: 25225063 DOI: 10.1158/1078-0432.CCR-13-1727] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
71 Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem 2011;18:2686-714. [PMID: 21649578 DOI: 10.2174/092986711796011229] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
72 Baer R, Cintas C, Therville N, Guillermet-Guibert J. Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter? Adv Biol Regul. 2015;59:19-35. [PMID: 26166735 DOI: 10.1016/j.jbior.2015.05.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
73 Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood 2013;121:4884-93. [PMID: 23637129 DOI: 10.1182/blood-2012-05-432252] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
74 Paz-Ares L, Blanco-Aparicio C, García-Carbonero R, Carnero A. Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol 2009;11:572-9. [PMID: 19775996 DOI: 10.1007/s12094-009-0407-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
75 Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell. 2016;29:75-89. [PMID: 26725216 DOI: 10.1016/j.ccell.2015.11.011] [Cited by in Crossref: 128] [Cited by in F6Publishing: 119] [Article Influence: 18.3] [Reference Citation Analysis]
76 Gupta RK, Johansson S. Fibronectin assembly in the crypts of cytokinesis-blocked multilobular cells promotes anchorage-independent growth. PLoS One 2013;8:e72933. [PMID: 23951336 DOI: 10.1371/journal.pone.0072933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
77 Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis. 2010;31:1165-1174. [PMID: 20047953 DOI: 10.1093/carcin/bgp337] [Cited by in Crossref: 82] [Cited by in F6Publishing: 83] [Article Influence: 6.8] [Reference Citation Analysis]
78 Tsolakos N, Durrant TN, Chessa T, Suire SM, Oxley D, Kulkarni S, Downward J, Perisic O, Williams RL, Stephens L, Hawkins PT. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proc Natl Acad Sci U S A 2018;115:12176-81. [PMID: 30442661 DOI: 10.1073/pnas.1803446115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
79 Riaz A, Ilan N, Vlodavsky I, Li JP, Johansson S. Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem 2013;288:12366-75. [PMID: 23504323 DOI: 10.1074/jbc.M112.435172] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
80 Kwon MC, Berns A. Mouse models for lung cancer. Mol Oncol 2013;7:165-77. [PMID: 23481268 DOI: 10.1016/j.molonc.2013.02.010] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 9.1] [Reference Citation Analysis]
81 Murugan AK, Grieco M, Tsuchida N. RAS mutations in human cancers: Roles in precision medicine. Semin Cancer Biol. 2019;59:23-35. [PMID: 31255772 DOI: 10.1016/j.semcancer.2019.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
82 van Veen JE, Scherzer M, Boshuizen J, Chu M, Liu A, Landman A, Green S, Trejo C, McMahon M. Mutationally-activated PI3'-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase. Elife 2019;8:e43668. [PMID: 31452510 DOI: 10.7554/eLife.43668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Potente M, Mäkinen T. Vascular heterogeneity and specialization in development and disease. Nat Rev Mol Cell Biol 2017;18:477-94. [PMID: 28537573 DOI: 10.1038/nrm.2017.36] [Cited by in Crossref: 217] [Cited by in F6Publishing: 198] [Article Influence: 43.4] [Reference Citation Analysis]
84 Light RW, Lee YG. Pneumothorax, Chylothorax, Hemothorax, and Fibrothorax. Murray and Nadel's Textbook of Respiratory Medicine. Elsevier; 2016. pp. 1439-1460.e10. [DOI: 10.1016/b978-1-4557-3383-5.00081-6] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
85 Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 2012;11:75. [PMID: 23039341 DOI: 10.1186/1476-4598-11-75] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
86 Sizek H, Hamel A, Deritei D, Campbell S, Ravasz Regan E. Boolean model of growth signaling, cell cycle and apoptosis predicts the molecular mechanism of aberrant cell cycle progression driven by hyperactive PI3K. PLoS Comput Biol 2019;15:e1006402. [PMID: 30875364 DOI: 10.1371/journal.pcbi.1006402] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
87 Soriano O, Alcón-Pérez M, Vicente-Manzanares M, Castellano E. The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction. Genes (Basel) 2021;12:819. [PMID: 34071831 DOI: 10.3390/genes12060819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Burke JE, Williams RL. Synergy in activating class I PI3Ks. Trends Biochem Sci 2015;40:88-100. [PMID: 25573003 DOI: 10.1016/j.tibs.2014.12.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 14.4] [Reference Citation Analysis]
89 Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev. 2013;93:1019-1137. [PMID: 23899561 DOI: 10.1152/physrev.00028.2012] [Cited by in Crossref: 875] [Cited by in F6Publishing: 790] [Article Influence: 97.2] [Reference Citation Analysis]
90 Witte MH, Dellinger MT, Papendieck CM, Boccardo F. Overlapping biomarkers, pathways, processes and syndromes in lymphatic development, growth and neoplasia. Clin Exp Metastasis 2012;29:707-27. [PMID: 22798218 DOI: 10.1007/s10585-012-9493-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Sampaio C, Dance M, Montagner A, Edouard T, Malet N, Perret B, Yart A, Salles JP, Raynal P. Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition. Mol Cell Biol 2008;28:587-600. [PMID: 18025104 DOI: 10.1128/MCB.01318-07] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
92 Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 2010;29:49-60. [PMID: 20108024 DOI: 10.1007/s10555-010-9209-4] [Cited by in Crossref: 152] [Cited by in F6Publishing: 137] [Article Influence: 12.7] [Reference Citation Analysis]
93 Bartman CM, Egelston J, Kattula S, Zeidner LC, D'Ippolito A, Doble BW, Phiel CJ. Gene Expression Profiling in Mouse Embryonic Stem Cells Reveals Glycogen Synthase Kinase-3-Dependent Targets of Phosphatidylinositol 3-Kinase and Wnt/β-Catenin Signaling Pathways. Front Endocrinol (Lausanne) 2014;5:133. [PMID: 25165462 DOI: 10.3389/fendo.2014.00133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
94 Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J. RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J Clin Invest 2014;124:3601-11. [PMID: 25003191 DOI: 10.1172/JCI74134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
95 Chen K, Shang Z, Dai AL, Dai PL. Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene. Life Sci 2020;255:117816. [PMID: 32454155 DOI: 10.1016/j.lfs.2020.117816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
96 Fan HY, Liu Z, Paquet M, Wang J, Lydon JP, DeMayo FJ, Richards JS. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 2009;69:6463-72. [PMID: 19679546 DOI: 10.1158/0008-5472.CAN-08-3363] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
97 Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schönhuber N, Planque L, Lulka H, Couderc B, Bousquet C, Garmy-Susini B. Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α. Genes Dev. 2014;28:2621-2635. [PMID: 25452273 DOI: 10.1101/gad.249409.114] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 10.9] [Reference Citation Analysis]
98 Dorard C, Vucak G, Baccarini M. Deciphering the RAS/ERK pathway in vivo. Biochem Soc Trans 2017;45:27-36. [PMID: 28202657 DOI: 10.1042/BST20160135] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
99 Götz R. Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression. Cancer Cell Int 2008;8:7. [PMID: 18492263 DOI: 10.1186/1475-2867-8-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
100 Fruman DA. Regulatory subunits of class IA PI3K. Curr Top Microbiol Immunol 2010;346:225-44. [PMID: 20563711 DOI: 10.1007/82_2010_39] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
101 Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, Zwang Y, Roberts TM, Root DE, Jacks T, Hahn WC. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014;158:171-84. [PMID: 24954536 DOI: 10.1016/j.cell.2014.06.004] [Cited by in Crossref: 423] [Cited by in F6Publishing: 418] [Article Influence: 52.9] [Reference Citation Analysis]
102 Jin J, Pawson T. Modular evolution of phosphorylation-based signalling systems. Philos Trans R Soc Lond B Biol Sci 2012;367:2540-55. [PMID: 22889906 DOI: 10.1098/rstb.2012.0106] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 10.1] [Reference Citation Analysis]
103 Fan HY, Richards JS. Minireview: physiological and pathological actions of RAS in the ovary. Mol Endocrinol 2010;24:286-98. [PMID: 19880654 DOI: 10.1210/me.2009-0251] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
104 Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 2009;4:e5717. [PMID: 19492075 DOI: 10.1371/journal.pone.0005717] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 7.2] [Reference Citation Analysis]
105 Cleary JM, Shapiro GI. Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer. Curr Oncol Rep 2010;12:87-94. [PMID: 20425592 DOI: 10.1007/s11912-010-0091-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
106 Zhu K, Yan H, Wang R, Zhu H, Meng X, Xu X, Dou X, Chen D. Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer.Med Oncol. 2014;31:16. [PMID: 24861917 DOI: 10.1007/s12032-014-0016-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
107 Pei D, Chen K, Liao H. Targeting Ras with Macromolecules. Cold Spring Harb Perspect Med 2018;8:a031476. [PMID: 28778966 DOI: 10.1101/cshperspect.a031476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
108 Solomon B, Pearson RB. Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. J Thorac Oncol 2009;4:787-91. [PMID: 19550242 DOI: 10.1097/JTO.0b013e3181a74dba] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
109 Walter G, Ruediger R. Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways. Cell Cycle 2012;11:451-9. [PMID: 22262169 DOI: 10.4161/cc.11.3.19057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
110 Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, Tsuchida A. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol. 1990;7:37-47. [PMID: 1964473 DOI: 10.1038/nrd2926] [Cited by in Crossref: 1691] [Cited by in F6Publishing: 1605] [Article Influence: 54.5] [Reference Citation Analysis]
111 Martins M, McCarthy A, Baxendale R, Guichard S, Magno L, Kessaris N, El-Bahrawy M, Yu P, Katan M. Tumor suppressor role of phospholipase C epsilon in Ras-triggered cancers. Proc Natl Acad Sci U S A 2014;111:4239-44. [PMID: 24591640 DOI: 10.1073/pnas.1311500111] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
112 Graupera M, Potente M. Regulation of angiogenesis by PI3K signaling networks. Exp Cell Res 2013;319:1348-55. [PMID: 23500680 DOI: 10.1016/j.yexcr.2013.02.021] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
113 Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010;16:2505-11. [PMID: 20388847 DOI: 10.1158/1078-0432.CCR-09-2229] [Cited by in Crossref: 166] [Cited by in F6Publishing: 105] [Article Influence: 13.8] [Reference Citation Analysis]
114 Tripathi K, Garg M. Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer. J Cell Commun Signal. 2018;12:513-527. [PMID: 29330773 DOI: 10.1007/s12079-017-0441-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
115 Pérez-García V, Redondo-Muñoz J, Kumar A, Carrera AC. Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity. Mol Cell Biol 2014;34:3359-73. [PMID: 24958106 DOI: 10.1128/MCB.00167-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
116 Hung PS, Huang MH, Kuo YY, Yang JC. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Cancers (Basel) 2020;12:E837. [PMID: 32244355 DOI: 10.3390/cancers12040837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Coso S, Bovay E, Petrova TV. Pressing the right buttons: signaling in lymphangiogenesis. Blood 2014;123:2614-24. [DOI: 10.1182/blood-2013-12-297317] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 8.5] [Reference Citation Analysis]
118 Sarris EG, Saif MW, Syrigos KN. The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) 2012;5:1236-64. [PMID: 24281308 DOI: 10.3390/ph5111236] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
119 Light RW, Lee YCG. Pneumothorax, Chylothorax, Hemothorax, and Fibrothorax. Murray and Nadel's Textbook of Respiratory Medicine. Elsevier; 2010. pp. 1764-91. [DOI: 10.1016/b978-1-4160-4710-0.00074-2] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
120 Naumann RW. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. Gynecologic Oncology 2011;123:411-20. [DOI: 10.1016/j.ygyno.2011.08.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
121 Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74. [PMID: 18725988 DOI: 10.1172/JCI34739] [Cited by in Crossref: 162] [Cited by in F6Publishing: 669] [Article Influence: 11.6] [Reference Citation Analysis]
122 Yellen P, Foster DA. Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells. Cancer Lett 2014;353:258-63. [PMID: 25086185 DOI: 10.1016/j.canlet.2014.07.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
123 Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9:517-531. [PMID: 18568040 DOI: 10.1038/nrm2438] [Cited by in Crossref: 977] [Cited by in F6Publishing: 899] [Article Influence: 69.8] [Reference Citation Analysis]
124 Wen L, Xie M. Spectroscopic investigation of the interaction between G-quadruplex of KRAS promoter sequence and three isoquinoline alkaloids. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2017;171:287-96. [DOI: 10.1016/j.saa.2016.08.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
125 Hollander MC, Maier CR, Hobbs EA, Ashmore AR, Linnoila RI, Dennis PA. Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene 2011;30:1812-21. [PMID: 21242979 DOI: 10.1038/onc.2010.556] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
126 Giudice FS, Squarize CH. The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen 2013;Suppl 5:003. [PMID: 25126449 DOI: 10.4172/2157-2518.S5-003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
127 Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, Kuo SH, Cheng AL, Teng CM. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357:582-590. [PMID: 25497009 DOI: 10.1016/j.canlet.2014.12.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
128 Akbari Dilmaghani N, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Bashash D. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies. IUBMB Life 2021;73:618-42. [PMID: 33476088 DOI: 10.1002/iub.2446] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
129 Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017;235:R43-61. [PMID: 28838947 DOI: 10.1530/JOE-17-0266] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 8.4] [Reference Citation Analysis]
130 Aslan O, Cremona M, Morgan C, Cheung LW, Mills GB, Hennessy BT. Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. BMC Cancer 2018;18:168. [PMID: 29426295 DOI: 10.1186/s12885-018-4035-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
131 Qin H, Liu L, Sun S, Zhang D, Sheng J, Li B, Yang W. The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. PeerJ 2018;6:e5092. [PMID: 29942710 DOI: 10.7717/peerj.5092] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
132 Torphy RJ, Tignanelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, Yeh JJ. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLoS One 2014;9:e89474. [PMID: 24586805 DOI: 10.1371/journal.pone.0089474] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
133 Michailidou C, Jones M, Walker P, Kamarashev J, Kelly A, Hurlstone AF. Dissecting the roles of Raf- and PI3K-signalling pathways in melanoma formation and progression in a zebrafish model. Dis Model Mech 2009;2:399-411. [PMID: 19470611 DOI: 10.1242/dmm.001149] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
134 Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, Scaglioni PP. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009;69:7644-7652. [PMID: 19789349 DOI: 10.1158/0008-5472.can-09-0823] [Cited by in Crossref: 117] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
135 Li Y, Yuan Y, Zhang F, Guo A, Cao F, Song M, Fu Y, Xu X, Shen H, Zheng S, Pan Y, Chang W. Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma. Front Pharmacol 2021;12:739501. [PMID: 34790119 DOI: 10.3389/fphar.2021.739501] [Reference Citation Analysis]
136 Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell 2017;170:17-33. [PMID: 28666118 DOI: 10.1016/j.cell.2017.06.009] [Cited by in Crossref: 552] [Cited by in F6Publishing: 494] [Article Influence: 110.4] [Reference Citation Analysis]
137 Yoshida S, Pacitto R, Sesi C, Kotula L, Swanson JA. Dorsal ruffles enhance activation of Akt by growth factors. J Cell Sci 2018;131:jcs220517. [PMID: 30333140 DOI: 10.1242/jcs.220517] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
138 Zeller KS, Idevall-Hagren O, Stefansson A, Velling T, Jackson SP, Downward J, Tengholm A, Johansson S. PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading. Cell Signal 2010;22:1838-48. [PMID: 20667469 DOI: 10.1016/j.cellsig.2010.07.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
139 Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012;26:1573-1586. [PMID: 22802530 DOI: 10.1101/gad.191973.112] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 9.3] [Reference Citation Analysis]
140 Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013;31:675-704. [PMID: 23330955 DOI: 10.1146/annurev-immunol-032712-095946] [Cited by in Crossref: 245] [Cited by in F6Publishing: 241] [Article Influence: 27.2] [Reference Citation Analysis]
141 Juvin V, Malek M, Anderson KE, Dion C, Chessa T, Lecureuil C, Ferguson GJ, Cosulich S, Hawkins PT, Stephens LR. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. PLoS One 2013;8:e75045. [PMID: 24124465 DOI: 10.1371/journal.pone.0075045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
142 Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 2014;124:2696-708. [PMID: 24762440 DOI: 10.1172/JCI72171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 63] [Article Influence: 10.5] [Reference Citation Analysis]
143 Smith MD, Sudhahar CG, Gong D, Stahelin RV, Best MD. Modular synthesis of biologically active phosphatidic acid probes using click chemistry. Mol Biosyst 2009;5:962-72. [PMID: 19668861 DOI: 10.1039/b901420a] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
144 Cuesta C, Arévalo-Alameda C, Castellano E. The Importance of Being PI3K in the RAS Signaling Network. Genes (Basel) 2021;12:1094. [PMID: 34356110 DOI: 10.3390/genes12071094] [Reference Citation Analysis]
145 Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011;10:806-16. [PMID: 21421804 DOI: 10.1158/1535-7163.MCT-10-1050] [Cited by in Crossref: 112] [Cited by in F6Publishing: 81] [Article Influence: 10.2] [Reference Citation Analysis]
146 Umesalma S, Sudhandiran G. Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. European Journal of Pharmacology 2011;660:249-58. [DOI: 10.1016/j.ejphar.2011.03.036] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
147 Scholl FA, Dumesic PA, Barragan DI, Charron J, Khavari PA. Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin. Oncogene 2009;28:1485-95. [PMID: 19198628 DOI: 10.1038/onc.2008.459] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
148 Fenton SE, Hutchens KA, Denning MF. Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell-cell adhesion. Mol Carcinog 2015;54:1181-93. [PMID: 24976598 DOI: 10.1002/mc.22190] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
149 Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010;10:130-7. [PMID: 20094047 DOI: 10.1038/nrc2787] [Cited by in Crossref: 508] [Cited by in F6Publishing: 470] [Article Influence: 42.3] [Reference Citation Analysis]
150 Yadav V, Denning MF. Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog. 2011;50:346-352. [PMID: 21480388 DOI: 10.1002/mc.20716] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 6.4] [Reference Citation Analysis]
151 Renner O, Blanco-Aparicio C, Carnero A. Genetic modelling of the PTEN/AKT pathway in cancer research. Clin Transl Oncol 2008;10:618-27. [PMID: 18940742 DOI: 10.1007/s12094-008-0262-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
152 White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ. KRAS insertion mutations are oncogenic and exhibit distinct functional properties. Nat Commun 2016;7:10647. [PMID: 26854029 DOI: 10.1038/ncomms10647] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
153 Barbacid M. Opening a new GATAway for treating KRAS-driven lung tumors. Cancer Cell 2012;21:598-600. [PMID: 22624710 DOI: 10.1016/j.ccr.2012.04.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
154 Nussinov R, Muratcioglu S, Tsai CJ, Jang H, Gursoy A, Keskin O. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Mol Cancer Res 2015;13:1265-73. [PMID: 26085527 DOI: 10.1158/1541-7786.MCR-15-0165] [Cited by in Crossref: 58] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
155 Park E, Park J, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. Int J Oncol. 2012;40:1259-1266. [PMID: 22159814 DOI: 10.3892/ijo.2011.1290] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
156 Vigil D, Martin TD, Williams F, Yeh JJ, Campbell SL, Der CJ. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms. J Biol Chem 2010;285:34729-40. [PMID: 20801877 DOI: 10.1074/jbc.M110.116756] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
157 Mann KM, Ying H, Juan J, Jenkins NA, Copeland NG. KRAS-related proteins in pancreatic cancer. Pharmacol Ther 2016;168:29-42. [PMID: 27595930 DOI: 10.1016/j.pharmthera.2016.09.003] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 11.5] [Reference Citation Analysis]
158 Murugan AK, Munirajan AK, Tsuchida N. Genetic deregulation of the PIK3CA oncogene in oral cancer. Cancer Lett. 2013;338:193-203. [PMID: 23597702 DOI: 10.1016/j.canlet.2013.04.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
159 Park SH, Kim JJ, Chung JS, Lee SR, Lee GY, Kim HJ, Yoo YD. RASSF1A suppresses the activated K-Ras-induced oxidative DNA damage. Biochem Biophys Res Commun 2011;408:149-53. [PMID: 21473856 DOI: 10.1016/j.bbrc.2011.03.139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
160 Sheridan C, Downward J. Inhibiting the RAS–PI3K Pathway in Cancer Therapy. Inhibitors of the Ras superfamily G-proteins, Part B. Elsevier; 2013. pp. 107-36. [DOI: 10.1016/b978-0-12-420146-0.00005-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
161 Francoz S, Mathiaux J, Dubus P. [The mouse as preclinical models of lung cancer]. Bull Cancer 2012;99:1017-27. [PMID: 23131302 DOI: 10.1684/bdc.2012.1657] [Reference Citation Analysis]
162 von Karstedt S, Walczak H. An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. Cell Death Discov 2020;6:14. [PMID: 32194994 DOI: 10.1038/s41420-020-0249-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
163 Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 226] [Article Influence: 40.2] [Reference Citation Analysis]
164 Law JW, Lee AY. The role of semaphorins and their receptors in gliomas. J Signal Transduct 2012;2012:902854. [PMID: 23050142 DOI: 10.1155/2012/902854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
165 Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Sci Signal 2013;6:ra105. [PMID: 24300897 DOI: 10.1126/scisignal.2004125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
166 Fehrenbacher N, Bar-Sagi D, Philips M. Ras/MAPK signaling from endomembranes. Mol Oncol 2009;3:297-307. [PMID: 19615955 DOI: 10.1016/j.molonc.2009.06.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 7.8] [Reference Citation Analysis]
167 Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell. 2013;23:406-420. [PMID: 23453624 DOI: 10.1016/j.ccr.2013.01.023] [Cited by in Crossref: 208] [Cited by in F6Publishing: 207] [Article Influence: 23.1] [Reference Citation Analysis]
168 Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009;106:2835-2840. [PMID: 19196980 DOI: 10.1073/pnas.0813351106] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 8.7] [Reference Citation Analysis]
169 Sanli T, Liu C, Rashid A, Hopmans SN, Tsiani E, Schultz C, Farrell T, Singh G, Wright J, Tsakiridis T. Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression. J Thorac Oncol 2011;6:439-50. [PMID: 21258249 DOI: 10.1097/JTO.0b013e3182049d8b] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
170 Charette N, Vandeputte C, Stärkel P. Ras in digestive oncology: from molecular biology to clinical implications. Current Opinion in Oncology 2014;26:454-61. [DOI: 10.1097/cco.0000000000000088] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
171 Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: From biology to therapy. Lung Cancer 2018;124:53-64. [PMID: 30268480 DOI: 10.1016/j.lungcan.2018.07.013] [Cited by in Crossref: 105] [Cited by in F6Publishing: 98] [Article Influence: 26.3] [Reference Citation Analysis]
172 Ghoshal P, Singla B, Lin H, Cherian-Shaw M, Tritz R, Padgett CA, Hudson F, Zhang H, Stansfield BK, Csányi G. Loss of GTPase activating protein neurofibromin stimulates paracrine cell communication via macropinocytosis. Redox Biol 2019;27:101224. [PMID: 31201114 DOI: 10.1016/j.redox.2019.101224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
173 Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E, Barbacid M. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 2010;29:1091-104. [PMID: 20150892 DOI: 10.1038/emboj.2010.7] [Cited by in Crossref: 189] [Cited by in F6Publishing: 164] [Article Influence: 15.8] [Reference Citation Analysis]
174 Hollander MC, Balogh AR, Liwanag J, Han W, Linnoila RI, Anver MR, Dennis PA. Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia 2008;10:866-72. [PMID: 18683321 DOI: 10.1593/neo.08406] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
175 Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene 2008;27:877-95. [PMID: 17724477 DOI: 10.1038/sj.onc.1210704] [Cited by in Crossref: 183] [Cited by in F6Publishing: 169] [Article Influence: 12.2] [Reference Citation Analysis]
176 Tomasini P, Walia P, Labbe C, Jao K, Leighl NB. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. Oncologist 2016;21:1450-60. [PMID: 27807303 DOI: 10.1634/theoncologist.2015-0084] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
177 Mäkinen T, Boon LM, Vikkula M, Alitalo K. Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies. Circ Res 2021;129:136-54. [PMID: 34166072 DOI: 10.1161/CIRCRESAHA.121.318142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
178 Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012;122:553-7. [PMID: 22214849 DOI: 10.1172/JCI59309] [Cited by in Crossref: 131] [Cited by in F6Publishing: 90] [Article Influence: 13.1] [Reference Citation Analysis]
179 Upton DH, Walters KA, Allavena RE, Jimenez M, Desai R, Handelsman DJ, Allan CM. Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice. Horm Cancer 2016;7:316-26. [PMID: 27506975 DOI: 10.1007/s12672-016-0272-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
180 Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res 2011;71:5965-75. [PMID: 21775521 DOI: 10.1158/0008-5472.CAN-11-0445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
181 Kelleher FC, Mcarthur GA. Targeting NRAS in Melanoma. The Cancer Journal 2012;18:132-6. [DOI: 10.1097/ppo.0b013e31824ba4df] [Cited by in Crossref: 52] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
182 Fan HY, Liu Z, Cahill N, Richards JS. Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 2008;22:2128-40. [PMID: 18606860 DOI: 10.1210/me.2008-0095] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 8.9] [Reference Citation Analysis]
183 Mathew G, Hannan A, Hertzler-Schaefer K, Wang F, Feng GS, Zhong J, Zhao JJ, Downward J, Zhang X. Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. Proc Natl Acad Sci U S A 2016;113:13156-61. [PMID: 27799550 DOI: 10.1073/pnas.1604450113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
184 Chiosea SI, Thompson LD, Weinreb I, Bauman JE, Mahaffey AM, Miller C, Ferris RL, Gooding WE. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer 2016;122:3136-44. [PMID: 27379604 DOI: 10.1002/cncr.30179] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
185 Du L, Shen J, Weems A, Lu SL. Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma. J Oncol 2012;2012:450179. [PMID: 22666248 DOI: 10.1155/2012/450179] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
186 Kern F, Doma E, Rupp C, Niault T, Baccarini M. Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis. Oncogene 2013;32:2483-92. [PMID: 22733131 DOI: 10.1038/onc.2012.254] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
187 Lu S, Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R, Zhang J. Ras Conformational Ensembles, Allostery, and Signaling. Chem Rev 2016;116:6607-65. [PMID: 26815308 DOI: 10.1021/acs.chemrev.5b00542] [Cited by in Crossref: 177] [Cited by in F6Publishing: 159] [Article Influence: 29.5] [Reference Citation Analysis]
188 Niland S, Eble JA. Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol 2012;2012:125278. [PMID: 21941547 DOI: 10.1155/2012/125278] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
189 Molina-Arcas M, Samani A, Downward J. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Genes (Basel) 2021;12:899. [PMID: 34200676 DOI: 10.3390/genes12060899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
190 Hervieu A, Kermorgant S. The Role of PI3K in Met Driven Cancer: A Recap. Front Mol Biosci 2018;5:86. [PMID: 30406111 DOI: 10.3389/fmolb.2018.00086] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
191 Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. Sci Transl Med 2017;9:eaal5253. [PMID: 28615361 DOI: 10.1126/scitranslmed.aal5253] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
192 Martini M, Vecchione L, Siena S, Tejpar S, Bardelli A. Targeted therapies: how personal should we go? Nat Rev Clin Oncol. 2012;9:87-97. [PMID: 22083042 DOI: 10.1038/nrclinonc.2011.164] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
193 Sadasivan C, Zhabyeyev P, Labib D, White JA, Paterson DI, Oudit GY. Cardiovascular toxicity of PI3Kα inhibitors. Clin Sci (Lond) 2020;134:2595-622. [PMID: 33063821 DOI: 10.1042/CS20200302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
194 Guberman E, Sherief H, Regan ER. Boolean model of anchorage dependence and contact inhibition points to coordinated inhibition but semi-independent induction of proliferation and migration. Comput Struct Biotechnol J 2020;18:2145-65. [PMID: 32913583 DOI: 10.1016/j.csbj.2020.07.016] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 2008;27:5477-5485. [PMID: 18794882 DOI: 10.1038/onc.2008.248] [Cited by in Crossref: 250] [Cited by in F6Publishing: 234] [Article Influence: 17.9] [Reference Citation Analysis]
196 Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 2009;106:22299-304. [PMID: 20007781 DOI: 10.1073/pnas.0905152106] [Cited by in Crossref: 214] [Cited by in F6Publishing: 200] [Article Influence: 16.5] [Reference Citation Analysis]
197 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
198 Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011;121:4311-21. [PMID: 21985784 DOI: 10.1172/JCI57909] [Cited by in Crossref: 149] [Cited by in F6Publishing: 106] [Article Influence: 13.5] [Reference Citation Analysis]
199 Shymanets A, Prajwal, Bucher K, Beer-Hammer S, Harteneck C, Nürnberg B. p87 and p101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity. J Biol Chem 2013;288:31059-68. [PMID: 24014027 DOI: 10.1074/jbc.M113.508234] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
200 Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, Wang S, Palakurthi S, Choi J, Ivanova EV, Leonardi GC, Ulrich BC, Paweletz CP, Kirschmeier PT, Watanabe M, Baba H, Nishino M, Nagy RJ, Lanman RB, Capelletti M, Chambers ES, Redig AJ, VanderLaan PA, Costa DB, Imamura Y, Jänne PA. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 2018;24:5963-76. [PMID: 30072474 DOI: 10.1158/1078-0432.CCR-18-0876] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 7.8] [Reference Citation Analysis]
201 Daaboul HE, Daher CF, Taleb RI, Boulos J, Bodman-smith K, Boukamp P, Shebaby WN, Dagher C, El-sibai M, Mroueh MA. β-2-himachalen-6-ol protects against skin cancer development in vitro and in vivo. Journal of Pharmacy and Pharmacology 2017;69:1552-64. [DOI: 10.1111/jphp.12796] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
202 Icard P, Coquerel A, Wu Z, Gligorov J, Fuks D, Fournel L, Lincet H, Simula L. Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update. Int J Mol Sci 2021;22:6587. [PMID: 34205414 DOI: 10.3390/ijms22126587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Aytes A, Mitrofanova A, Kinkade CW, Lefebvre C, Lei M, Phelan V, LeKaye HC, Koutcher JA, Cardiff RD, Califano A. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci USA. 2013;110:E3506-E3515. [PMID: 23918374 DOI: 10.1073/pnas.1303558110] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 9.0] [Reference Citation Analysis]
204 Oliver G, Srinivasan RS. Lymphatic Vasculature Development. Annals of the New York Academy of Sciences 2008;1131:75-81. [DOI: 10.1196/annals.1413.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
205 Toulany M, Iida M, Keinath S, Iyi FF, Mueck K, Fehrenbacher B, Mansour WY, Schaller M, Wheeler DL, Rodemann HP. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Oncotarget 2016;7:43746-61. [PMID: 27248324 DOI: 10.18632/oncotarget.9670] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
206 Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, Mak TW. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA. 2010;107:13984-13990. [PMID: 20679220 DOI: 10.1073/pnas.1008136107] [Cited by in Crossref: 147] [Cited by in F6Publishing: 136] [Article Influence: 12.3] [Reference Citation Analysis]
207 Mellor P, Furber L, Nyarko J, Anderson D. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking. Biochemical Journal 2012;441:23-37. [DOI: 10.1042/bj20111164] [Cited by in Crossref: 63] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
208 Wang B, Jie Z, Joo D, Ordureau A, Liu P, Gan W, Guo J, Zhang J, North BJ, Dai X, Cheng X, Bian X, Zhang L, Harper JW, Sun SC, Wei W. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling. Nature 2017;545:365-9. [PMID: 28489822 DOI: 10.1038/nature22344] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 15.2] [Reference Citation Analysis]
209 Shin MK, Payne S, Bilger A, Matkowskyj KA, Carchman E, Meyer DS, Bentires-Alj M, Deming DA, Lambert PF. Activating Mutations in Pik3ca Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes. Clin Cancer Res 2019;25:1889-900. [PMID: 30530704 DOI: 10.1158/1078-0432.CCR-18-2843] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
210 Ramjaun AR, Hodivala-Dilke K. The role of cell adhesion pathways in angiogenesis. Int J Biochem Cell Biol 2009;41:521-30. [PMID: 18762270 DOI: 10.1016/j.biocel.2008.05.030] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
211 Rohlenova K, Neuzil J, Rohlena J. The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria. Biological Chemistry 2016;397:607-15. [DOI: 10.1515/hsz-2016-0130] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
212 Dbouk HA, Backer JM. Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase. Trends Pharmacol Sci 2013;34:149-53. [PMID: 23411347 DOI: 10.1016/j.tips.2012.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
213 Siempelkamp BD, Rathinaswamy MK, Jenkins ML, Burke JE. Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas. J Biol Chem 2017;292:12256-66. [PMID: 28515318 DOI: 10.1074/jbc.M117.789263] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 7.2] [Reference Citation Analysis]
214 Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A, Stratford AL, Lam WL, Berquin IM, Duronio V, Dunn SE. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 2009;28:2406-18. [PMID: 19430491 DOI: 10.1038/onc.2009.81] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
215 Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev. 2010;20:87-90. [PMID: 20006486 DOI: 10.1016/j.gde.2009.11.002] [Cited by in Crossref: 373] [Cited by in F6Publishing: 351] [Article Influence: 28.7] [Reference Citation Analysis]
216 Milton CK, Self AJ, Clarke PA, Banerji U, Piccioni F, Root DE, Whittaker SR. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer. Mol Cancer Ther 2020;19:1423-35. [PMID: 32371585 DOI: 10.1158/1535-7163.MCT-19-1131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
217 Zeestraten EC, Kuppen PJ, van de Velde CJ, Marijnen CA. Prediction in rectal cancer. Semin Radiat Oncol. 2012;22:175-183. [PMID: 22385923 DOI: 10.1016/j.semradonc.2011.12.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
218 Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-562. [PMID: 19629070 DOI: 10.1038/nrc2664] [Cited by in Crossref: 1656] [Cited by in F6Publishing: 1569] [Article Influence: 127.4] [Reference Citation Analysis]
219 Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010;20:697-706. [PMID: 20578891 DOI: 10.1089/thy.2010.1646] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 14.9] [Reference Citation Analysis]
220 Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 2014;25:697-710. [PMID: 24746704 DOI: 10.1016/j.ccr.2014.03.011] [Cited by in Crossref: 171] [Cited by in F6Publishing: 151] [Article Influence: 21.4] [Reference Citation Analysis]
221 Malanga D, Belmonte S, Colelli F, Scarfò M, De Marco C, Oliveira DM, Mirante T, Camastra C, Gagliardi M, Rizzuto A, Mignogna C, Paciello O, Papparella S, Fagman H, Viglietto G. AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer. PLoS One 2016;11:e0147334. [PMID: 26859676 DOI: 10.1371/journal.pone.0147334] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
222 Cayron C, Guillermet-Guibert J. The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients. Clin Res Hepatol Gastroenterol 2021;45:101473. [PMID: 32593694 DOI: 10.1016/j.clinre.2020.05.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
223 Burke JE. Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. Molecular Cell 2018;71:653-73. [DOI: 10.1016/j.molcel.2018.08.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 19.3] [Reference Citation Analysis]
224 Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009;458:725-31. [PMID: 19279572 DOI: 10.1038/nature07782] [Cited by in Crossref: 319] [Cited by in F6Publishing: 287] [Article Influence: 24.5] [Reference Citation Analysis]
225 Hayes TK, Der CJ. Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of RAS Mutant Cancers. In: Wittinghofer A, editor. Ras Superfamily Small G Proteins: Biology and Mechanisms 1. Vienna: Springer; 2014. pp. 135-56. [DOI: 10.1007/978-3-7091-1806-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
226 Sadeghi N, Gerber DE. Targeting the PI3K pathway for cancer therapy. Future Med Chem 2012;4:1153-69. [PMID: 22709255 DOI: 10.4155/fmc.12.56] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
227 Akula MK, Shi M, Jiang Z, Foster CE, Miao D, Li AS, Zhang X, Gavin RM, Forde SD, Germain G, Carpenter S, Rosadini CV, Gritsman K, Chae JJ, Hampton R, Silverman N, Gravallese EM, Kagan JC, Fitzgerald KA, Kastner DL, Golenbock DT, Bergo MO, Wang D. Control of the innate immune response by the mevalonate pathway. Nat Immunol 2016;17:922-9. [PMID: 27270400 DOI: 10.1038/ni.3487] [Cited by in Crossref: 112] [Cited by in F6Publishing: 93] [Article Influence: 18.7] [Reference Citation Analysis]
228 Tsutsumi K, Fujioka Y, Tsuda M, Kawaguchi H, Ohba Y. Visualization of Ras-PI3K interaction in the endosome using BiFC. Cell Signal 2009;21:1672-9. [PMID: 19616621 DOI: 10.1016/j.cellsig.2009.07.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
229 Arcucci S, Ramos-delgado F, Cayron C, Therville N, Gratacap M, Basset C, Thibault B, Guillermet-guibert J. Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent. Biochemical Journal 2021;478:1199-225. [DOI: 10.1042/bcj20210004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
230 Thevathasan JV, Tan E, Zheng H, Lin YC, Li Y, Inoue T, Fivaz M. The small GTPase HRas shapes local PI3K signals through positive feedback and regulates persistent membrane extension in migrating fibroblasts. Mol Biol Cell 2013;24:2228-37. [PMID: 23676667 DOI: 10.1091/mbc.E12-12-0905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
231 Wong KA, Russo A, Wang X, Chen YJ, Lavie A, O'Bryan JP. A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2β) regulation. PLoS One 2012;7:e45360. [PMID: 23028960 DOI: 10.1371/journal.pone.0045360] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
232 Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A 2013;110:4015-20. [PMID: 23431193 DOI: 10.1073/pnas.1216013110] [Cited by in Crossref: 145] [Cited by in F6Publishing: 139] [Article Influence: 16.1] [Reference Citation Analysis]
233 Upadhyaya P, Qian Z, Selner NG, Clippinger SR, Wu Z, Briesewitz R, Pei D. Inhibition of Ras Signaling by Blocking Ras-Effector Interactions with Cyclic Peptides. Angew Chem 2015;127:7712-6. [DOI: 10.1002/ange.201502763] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
234 Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene. 2008;27:5527-5541. [PMID: 18794886 DOI: 10.1038/onc.2008.247] [Cited by in Crossref: 565] [Cited by in F6Publishing: 541] [Article Influence: 40.4] [Reference Citation Analysis]
235 Icard P, Alifano M, Donnadieu E, Simula L. Fructose-1,6-bisphosphate promotes PI3K and glycolysis in T cells? Trends Endocrinol Metab 2021;32:540-3. [PMID: 34016523 DOI: 10.1016/j.tem.2021.04.013] [Reference Citation Analysis]
236 Arteaga CL. Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Curr Top Microbiol Immunol 2010;347:189-208. [PMID: 20593313 DOI: 10.1007/82_2010_54] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
237 Nussinov R, Zhang M, Tsai CJ, Liao TJ, Fushman D, Jang H. Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention. Biophys Rev 2018;10:1263-82. [PMID: 30269291 DOI: 10.1007/s12551-018-0461-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
238 Castellano E, Downward J. RAS Interaction with PI3K: More Than Just Another Effector Pathway. Genes Cancer 2011;2:261-74. [PMID: 21779497 DOI: 10.1177/1947601911408079] [Cited by in Crossref: 412] [Cited by in F6Publishing: 398] [Article Influence: 37.5] [Reference Citation Analysis]
239 Easty DJ, Gray SG, O'Byrne KJ, O'Donnell D, Bennett DC. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res 2011;24:446-61. [PMID: 21320293 DOI: 10.1111/j.1755-148X.2011.00836.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
240 Kitano S, Myers J, Nakamura J, Yamane A, Yamashita M, Nakayama M, Tsukahara Y, Ushida H, Liu W, Ratain MJ. A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PLoS One. 2013;8:e62989. [PMID: 23671647 DOI: 10.1371/journal.pone.0062989] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
241 Shymanets A, Prajwal, Vadas O, Czupalla C, LoPiccolo J, Brenowitz M, Ghigo A, Hirsch E, Krause E, Wetzker R, Williams RL, Harteneck C, Nürnberg B. Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity. Biochem J 2015;469:59-69. [PMID: 26173259 DOI: 10.1042/BJ20150099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
242 Tonlaar N, Galoforo S, Thibodeau BJ, Ahmed S, Wilson TG, Yumpo Cardenas P, Marples B, Wilson GD. Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer. Radiother Oncol 2017;124:504-12. [PMID: 28823407 DOI: 10.1016/j.radonc.2017.08.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
243 Sevick-Muraca EM, King PD. Lymphatic vessel abnormalities arising from disorders of Ras signal transduction. Trends Cardiovasc Med 2014;24:121-7. [PMID: 24183794 DOI: 10.1016/j.tcm.2013.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
244 Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, Gschwend JE, Retz M. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One 2011;6:e27509. [PMID: 22110663 DOI: 10.1371/journal.pone.0027509] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
245 Kim MJ, Lee SJ, Ryu JH, Kim SH, Kwon IC, Roberts TM. Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment. J Control Release 2020;318:98-108. [PMID: 31838203 DOI: 10.1016/j.jconrel.2019.12.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
246 Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61. [PMID: 20100961 DOI: 10.1200/JCO.2009.24.6116] [Cited by in Crossref: 477] [Cited by in F6Publishing: 239] [Article Influence: 39.8] [Reference Citation Analysis]
247 Bernier-Latmani J, Petrova TV. Intestinal lymphatic vasculature: structure, mechanisms and functions. Nat Rev Gastroenterol Hepatol 2017;14:510-26. [PMID: 28655884 DOI: 10.1038/nrgastro.2017.79] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 14.6] [Reference Citation Analysis]
248 Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, Doan HQ, Weiss HL, Evers BM. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 2010;210:767-776, 776-778. [PMID: 20421047 DOI: 10.1016/j.jamcollsurg.2009.12.008] [Cited by in Crossref: 133] [Cited by in F6Publishing: 147] [Article Influence: 11.1] [Reference Citation Analysis]
249 Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget 2011;2:435-47. [PMID: 21646685 DOI: 10.18632/oncotarget.285] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
250 Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 2008;14:180-92. [PMID: 18691552 DOI: 10.1016/j.ccr.2008.06.014] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 5.4] [Reference Citation Analysis]
251 Janas ML, Turner M. Interaction of Ras with p110γ is required for thymic β-selection in the mouse. J Immunol 2011;187:4667-75. [PMID: 21930962 DOI: 10.4049/jimmunol.1101949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
252 Eng J, Woo KM, Sima CS, Plodkowski A, Hellmann MD, Chaft JE, Kris MG, Arcila ME, Ladanyi M, Drilon A. Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas. J Thorac Oncol 2015;10:1713-9. [PMID: 26334752 DOI: 10.1097/JTO.0000000000000671] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
253 McCormick F. K-Ras protein as a drug target. J Mol Med (Berl) 2016;94:253-8. [PMID: 26960760 DOI: 10.1007/s00109-016-1382-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 9.7] [Reference Citation Analysis]
254 Sheridan C, Downward J. Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer. Curr Protoc Pharmacol 2015;70:14.35.1-14.35.16. [PMID: 26331885 DOI: 10.1002/0471141755.ph1435s70] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
255 Iyer D, Jannaway M, Yang Y, P Scallan J. Lymphatic Valves and Lymph Flow in Cancer-Related Lymphedema. Cancers (Basel) 2020;12:E2297. [PMID: 32824219 DOI: 10.3390/cancers12082297] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
256 Irvine WA, Flanagan JU, Allison JR. Computational Prediction of Amino Acids Governing Protein-Membrane Interaction for the PIP3 Cell Signaling System. Structure 2019;27:371-380.e3. [DOI: 10.1016/j.str.2018.10.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
257 Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Grönroos E, Lassailly F, Stamp G, Downward J. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance. Cancer Cell 2013;24:617-30. [PMID: 24229709 DOI: 10.1016/j.ccr.2013.09.012] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 14.6] [Reference Citation Analysis]
258 Tago K, Ohta S, Aoki-Ohmura C, Funakoshi-Tago M, Sashikawa M, Matsui T, Miyamoto Y, Wada T, Oshio T, Komine M, Matsugi J, Furukawa Y, Ohtsuki M, Yamauchi J, Yanagisawa K. K15 promoter-driven enforced expression of NKIRAS exhibits tumor suppressive activity against the development of DMBA/TPA-induced skin tumors. Sci Rep 2021;11:20658. [PMID: 34667224 DOI: 10.1038/s41598-021-00200-1] [Reference Citation Analysis]
259 Hosking B, Makinen T. Lymphatic vasculature: a molecular perspective. Bioessays 2007;29:1192-202. [PMID: 18008374 DOI: 10.1002/bies.20672] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
260 Zhu Z, Golay HG, Barbie DA. Targeting pathways downstream of KRAS in lung adenocarcinoma. Pharmacogenomics 2014;15:1507-18. [PMID: 25303301 DOI: 10.2217/pgs.14.108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
261 Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7-24. [PMID: 25533673 DOI: 10.1038/nrc3860] [Cited by in Crossref: 709] [Cited by in F6Publishing: 657] [Article Influence: 101.3] [Reference Citation Analysis]
262 Dornan GL, Burke JE. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. Front Immunol 2018;9:575. [PMID: 29616047 DOI: 10.3389/fimmu.2018.00575] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
263 Campa CC, Ciraolo E, Ghigo A, Germena G, Hirsch E. Crossroads of PI3K and Rac pathways. Small GTPases 2015;6:71-80. [PMID: 25942647 DOI: 10.4161/21541248.2014.989789] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
264 Ortolani S, Ciccarese C, Cingarlini S, Tortora G, Massari F. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. Future Oncol 2015;11:1809-28. [PMID: 26075448 DOI: 10.2217/fon.15.81] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
265 Li L, Möbitz S, Winter R. Characterization of the Spatial Organization of Raf Isoforms Interacting with K-Ras4B in the Lipid Membrane. Langmuir 2020;36:5944-53. [PMID: 32390436 DOI: 10.1021/acs.langmuir.0c00770] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
266 Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009;16:368-377. [PMID: 18846109 DOI: 10.1038/cdd.2008.148] [Cited by in Crossref: 287] [Cited by in F6Publishing: 272] [Article Influence: 20.5] [Reference Citation Analysis]
267 Xu H, Lee MS, Tsai PY, Adler AS, Curry NL, Challa S, Freinkman E, Hitchcock DS, Copps KD, White MF, Bronson RT, Marcotrigiano M, Wu Y, Clish CB, Kalaany NY. Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis. Proc Natl Acad Sci U S A 2018;115:4228-33. [PMID: 29610318 DOI: 10.1073/pnas.1718414115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
268 Ricciuti B, Leonardi GC, Metro G, Grignani F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A, Zicari D, Crinò L. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Rev Respir Med 2016;10:53-68. [PMID: 26714748 DOI: 10.1586/17476348.2016.1115349] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
269 Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biol Ther 2011;11:358-67. [PMID: 21124076 DOI: 10.4161/cbt.11.3.14227] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
270 Ichise T, Yoshida N, Ichise H. H-, N- and Kras cooperatively regulate lymphatic vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice. Development 2010;137:1003-13. [PMID: 20179099 DOI: 10.1242/dev.043489] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
271 Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One. 2012;7:e44146. [PMID: 22952903 DOI: 10.1371/journal.pone.0044146] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
272 Fuentes G, Valencia A. Ras classical effectors: new tales from in silico complexes. Trends Biochem Sci 2009;34:533-9. [PMID: 19801192 DOI: 10.1016/j.tibs.2009.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
273 Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, Wick MJ, Cutler RE Jr, Lalani AS, Bryce R, Auerbach A, Hanker AB, Arteaga CL. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer Cell 2020;37:183-199.e5. [PMID: 31978326 DOI: 10.1016/j.ccell.2019.12.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
274 Liu L. The NOK Receptor Family. In: Wheeler DL, Yarden Y, editors. Receptor Tyrosine Kinases: Family and Subfamilies. Cham: Springer International Publishing; 2015. pp. 843-59. [DOI: 10.1007/978-3-319-11888-8_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
275 Yang HW, Shin MG, Lee S, Kim JR, Park WS, Cho KH, Meyer T, Heo WD. Cooperative activation of PI3K by Ras and Rho family small GTPases. Mol Cell 2012;47:281-90. [PMID: 22683270 DOI: 10.1016/j.molcel.2012.05.007] [Cited by in Crossref: 109] [Cited by in F6Publishing: 107] [Article Influence: 10.9] [Reference Citation Analysis]
276 Ersahin T, Tuncbag N, Cetin-atalay R. The PI3K/AKT/mTOR interactive pathway. Mol BioSyst 2015;11:1946-54. [DOI: 10.1039/c5mb00101c] [Cited by in Crossref: 147] [Cited by in F6Publishing: 84] [Article Influence: 21.0] [Reference Citation Analysis]
277 Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. J Clin Invest 2014;124:1794-809. [PMID: 24569456 DOI: 10.1172/JCI69927] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
278 Uras IZ, Moll HP, Casanova E. Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. Int J Mol Sci 2020;21:E4325. [PMID: 32560574 DOI: 10.3390/ijms21124325] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
279 Rodriguez-salas N, Dominguez G, Barderas R, Mendiola M, García-albéniz X, Maurel J, Batlle JF. Clinical relevance of colorectal cancer molecular subtypes. Critical Reviews in Oncology/Hematology 2017;109:9-19. [DOI: 10.1016/j.critrevonc.2016.11.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
280 Yamamoto-Ibusuki M, Arnedos M, André F. Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Med 2015;13:137. [PMID: 26059247 DOI: 10.1186/s12916-015-0369-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
281 Mallucci L, Shi DY, Davies D, Jordan P, Nicol A, Lotti L, Mariani-Costantini R, Verginelli F, Wells V, Zicha D. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo. Mol Cancer Ther 2012;11:1884-93. [PMID: 22752425 DOI: 10.1158/1535-7163.MCT-11-1041-T] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
282 Knight ZA, Feldman ME, Balla A, Balla T, Shokat KM. A membrane capture assay for lipid kinase activity. Nat Protoc 2007;2:2459-66. [PMID: 17947987 DOI: 10.1038/nprot.2007.361] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
283 Martin-Fernandez C, Bales J, Hodgkinson C, Welman A, Welham MJ, Dive C, Morrow CJ. Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs. Mol Cancer Res 2009;7:955-65. [PMID: 19509113 DOI: 10.1158/1541-7786.MCR-08-0445] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
284 Fernandes MS, Melo S, Velho S, Carneiro P, Carneiro F, Seruca R. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. Oncotarget 2016;7:68546-58. [PMID: 27602501 DOI: 10.18632/oncotarget.11843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
285 Nair A, Kubatzky KF, Saha B. Ras Isoforms from Lab Benches to Lives-What Are We Missing and How Far Are We? Int J Mol Sci 2021;22:6508. [PMID: 34204435 DOI: 10.3390/ijms22126508] [Reference Citation Analysis]
286 Ihle NT, Powis G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 2010;31:135-44. [PMID: 20176047 DOI: 10.1016/j.mam.2010.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
287 Willecke M, Toggweiler J, Basler K. Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model. Oncogene 2011;30:4067-74. [PMID: 21516128 DOI: 10.1038/onc.2011.125] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
288 Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, Scholl C. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012;209:697-711. [PMID: 22451720 DOI: 10.1084/jem.20111910] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
289 Castellano E, Molina-Arcas M, Krygowska AA, East P, Warne P, Nicol A, Downward J. RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression. Nat Commun 2016;7:11245. [PMID: 27071537 DOI: 10.1038/ncomms11245] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
290 Liu X, Xu Y, Zhou Q, Chen M, Zhang Y, Liang H, Zhao J, Zhong W, Wang M. PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. Future Oncol. 2018;14:665-674. [PMID: 29219001 DOI: 10.2217/fon-2017-0588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
291 Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150. [PMID: 18767981 DOI: 10.1146/annurev.pathol.4.110807.092311] [Cited by in Crossref: 723] [Cited by in F6Publishing: 702] [Article Influence: 55.6] [Reference Citation Analysis]
292 Kim M. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Small GTPases 2010;1:161-4. [PMID: 21686270 DOI: 10.4161/sgtp.1.3.14344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
293 Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2011;2:359-72. [PMID: 21779505 DOI: 10.1177/1947601911412376] [Cited by in Crossref: 228] [Cited by in F6Publishing: 204] [Article Influence: 20.7] [Reference Citation Analysis]
294 Nuss JM, Lew Tsuhako A, Anand NK. Chapter 17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases. Annual Reports in Medicinal Chemistry Volume 44. Elsevier; 2009. pp. 339-56. [DOI: 10.1016/s0065-7743(09)04417-0] [Cited by in Crossref: 15] [Article Influence: 1.2] [Reference Citation Analysis]
295 Liu Q, Zheng J, Yin DD, Xiang J, He F, Wang YC, Liang L, Qin HY, Liu L, Liang YM, Han H. Monocyte to macrophage differentiation-associated (MMD) positively regulates ERK and Akt activation and TNF-α and NO production in macrophages. Mol Biol Rep 2012;39:5643-50. [PMID: 22203480 DOI: 10.1007/s11033-011-1370-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
296 Ritter M, Bresgen N, Kerschbaum HH. From Pinocytosis to Methuosis-Fluid Consumption as a Risk Factor for Cell Death. Front Cell Dev Biol 2021;9:651982. [PMID: 34249909 DOI: 10.3389/fcell.2021.651982] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
297 Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74. [PMID: 18725988 DOI: 10.1172/JCI34739] [Reference Citation Analysis]
298 Cataisson C, Salcedo R, Hakim S, Moffitt BA, Wright L, Yi M, Stephens R, Dai RM, Lyakh L, Schenten D, Yuspa HS, Trinchieri G. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med 2012;209:1689-702. [PMID: 22908325 DOI: 10.1084/jem.20101355] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 7.6] [Reference Citation Analysis]
299 Mita H, Toyota M, Aoki F, Akashi H, Maruyama R, Sasaki Y, Suzuki H, Idogawa M, Kashima L, Yanagihara K. A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Cancer. 2009;9:198. [PMID: 19545448 DOI: 10.1186/1471-2407-9-198] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
300 Mor A, Philips MR, Pillinger MH. The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis. Clin Immunol 2007;125:215-23. [PMID: 17913587 DOI: 10.1016/j.clim.2007.08.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
301 El Hallani S, Udager AM, Bell D, Fonseca I, Thompson LDR, Assaad A, Agaimy A, Luvison AM, Miller C, Seethala RR, Chiosea S. Epithelial-Myoepithelial Carcinoma: Frequent Morphologic and Molecular Evidence of Preexisting Pleomorphic Adenoma, Common HRAS Mutations in PLAG1-intact and HMGA2-intact Cases, and Occasional TP53, FBXW7, and SMARCB1 Alterations in High-grade Cases. Am J Surg Pathol 2018;42:18-27. [PMID: 29135520 DOI: 10.1097/PAS.0000000000000933] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 5.4] [Reference Citation Analysis]
302 Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One 2008;3:e2220. [PMID: 18493606 DOI: 10.1371/journal.pone.0002220] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
303 Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, Chin L, Kim M. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 2010;29:6222-32. [PMID: 20711233 DOI: 10.1038/onc.2010.349] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
304 Zhang B, Luk C, Valadares J, Aronis C, Foukas LC. Dominant Role of PI3K p110α over p110β in Insulin and β-Adrenergic Receptor Signalling. Int J Mol Sci 2021;22:12813. [PMID: 34884613 DOI: 10.3390/ijms222312813] [Reference Citation Analysis]
305 Roth Flach RJ, Guo CA, Danai LV, Yawe JC, Gujja S, Edwards YJ, Czech MP. Endothelial Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 Is Critical for Lymphatic Vascular Development and Function. Mol Cell Biol 2016;36:1740-9. [PMID: 27044870 DOI: 10.1128/MCB.01121-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
306 Musteanu M, Blaas L, Zenz R, Svinka J, Hoffmann T, Grabner B, Schramek D, Kantner HP, Müller M, Kolbe T, Rülicke T, Moriggl R, Kenner L, Stoiber D, Penninger JM, Popper H, Casanova E, Eferl R. A mouse model to identify cooperating signaling pathways in cancer. Nat Methods 2012;9:897-900. [PMID: 22863881 DOI: 10.1038/nmeth.2130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
307 Fang B. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochim Biophys Sin (Shanghai) 2016;48:27-38. [PMID: 26350096 DOI: 10.1093/abbs/gmv090] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
308 Cho KJ, Hill MM, Chigurupati S, Du G, Parton RG, Hancock JF. Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. Mol Cell Biol 2011;31:1110-20. [PMID: 21245384 DOI: 10.1128/MCB.00989-10] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
309 Drosten M, Barbacid M. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets. J Mol Med 2016;94:121-35. [DOI: 10.1007/s00109-015-1360-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
310 Wymann M. PI3Ks—Drug Targets in Inflammation and Cancer. In: Balla T, Wymann M, York JD, editors. Phosphoinositides I: Enzymes of Synthesis and Degradation. Dordrecht: Springer Netherlands; 2012. pp. 111-81. [DOI: 10.1007/978-94-007-3012-0_5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
311 Zhang M, Jang H, Nussinov R. The structural basis for Ras activation of PI3Kα lipid kinase. Phys Chem Chem Phys 2019;21:12021-8. [PMID: 31135801 DOI: 10.1039/c9cp00101h] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 9.3] [Reference Citation Analysis]
312 Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009;8:1-9. [PMID: 19139107 DOI: 10.1158/1535-7163.MCT-08-0801] [Cited by in Crossref: 130] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
313 Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013;3:548-63. [PMID: 23454899 DOI: 10.1158/2159-8290.CD-12-0446] [Cited by in Crossref: 116] [Cited by in F6Publishing: 70] [Article Influence: 12.9] [Reference Citation Analysis]
314 Baluk P, Yao LC, Flores JC, Choi D, Hong YK, McDonald DM. Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight. 2017;2. [PMID: 28814666 DOI: 10.1172/jci.insight.90103] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
315 Burger NB, Bekker MN, de Groot CJM, Christoffels VM, Haak MC. Why increased nuchal translucency is associated with congenital heart disease: a systematic review on genetic mechanisms: The fetal heart and nuchal edema: underlying genetic mechanisms. Prenat Diagn 2015;35:517-28. [DOI: 10.1002/pd.4586] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
316 Nussinov R, Zhang M, Tsai C, Jang H. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:2304-14. [DOI: 10.1016/j.bbadis.2017.10.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
317 Cueni LN, Detmar M. The lymphatic system in health and disease. Lymphat Res Biol 2008;6:109-22. [PMID: 19093783 DOI: 10.1089/lrb.2008.1008] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 12.6] [Reference Citation Analysis]
318 Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, Baker SJ, Cosenza SC, Basu I, Gupta YK, Reddy MV, Ueno L, Hart JR, Vogt PK, Mulholland D, Guha C, Aggarwal AK, Reddy EP. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell 2016;165:643-55. [PMID: 27104980 DOI: 10.1016/j.cell.2016.03.045] [Cited by in Crossref: 171] [Cited by in F6Publishing: 160] [Article Influence: 28.5] [Reference Citation Analysis]
319 Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol. 2010;346:143-169. [PMID: 20563706 DOI: 10.1007/82_2010_56] [Cited by in Crossref: 21] [Cited by in F6Publishing: 60] [Article Influence: 1.9] [Reference Citation Analysis]
320 Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev 2009;19:4-11. [PMID: 19201597 DOI: 10.1016/j.gde.2008.12.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
321 Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013;73:3248-3261. [PMID: 23580570 DOI: 10.1158/0008-5472.can-12-1578] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
322 Bellier J, Nokin MJ, Caprasse M, Tiamiou A, Blomme A, Scheijen JL, Koopmansch B, MacKay GM, Chiavarina B, Costanza B, Rademaker G, Durieux F, Agirman F, Maloujahmoum N, Cusumano PG, Lovinfosse P, Leung HY, Lambert F, Bours V, Schalkwijk CG, Hustinx R, Peulen O, Castronovo V, Bellahcène A. Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab. Cell Rep 2020;30:1400-1416.e6. [PMID: 32023458 DOI: 10.1016/j.celrep.2020.01.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
323 Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F. Ras signaling and therapies. Adv Cancer Res. 2009;102:1-17. [PMID: 19595305 DOI: 10.1016/s0065-230x(09)02001-6] [Cited by in Crossref: 146] [Cited by in F6Publishing: 110] [Article Influence: 11.2] [Reference Citation Analysis]
324 Yu M, Grady WM. Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol 2012;5:319-37. [PMID: 22973417 DOI: 10.1177/1756283X12448456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
325 Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT, Moscat J. The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 2008;13:343-54. [PMID: 18394557 DOI: 10.1016/j.ccr.2008.02.001] [Cited by in Crossref: 400] [Cited by in F6Publishing: 383] [Article Influence: 28.6] [Reference Citation Analysis]
326 Stamatkin C, Ratermann KL, Overley CW, Black EP. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol Ther 2015;16:1341-52. [PMID: 26176612 DOI: 10.1080/15384047.2015.1070986] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
327 Man JH, Liang B, Gu YX, Zhou T, Li AL, Li T, Jin BF, Bai B, Zhang HY, Zhang WN, Li WH, Gong WL, Li HY, Zhang XM. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J Clin Invest 2010;120:2829-41. [PMID: 20628200 DOI: 10.1172/JCI42542] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
328 Citi V, Del Re M, Martelli A, Calderone V, Breschi MC, Danesi R. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro. Cancer Chemother Pharmacol 2018;81:745-54. [PMID: 29476223 DOI: 10.1007/s00280-018-3543-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
329 Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC. Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Dev Dyn. 2009;238:2670-2679. [PMID: 19705443 DOI: 10.1002/dvdy.22078] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
330 McCormick F. Cancer therapy based on oncogene addiction. J Surg Oncol 2011;103:464-7. [PMID: 21480237 DOI: 10.1002/jso.21749] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
331 Oak JS, Chen J, Peralta RQ, Deane JA, Fruman DA. The p85β regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. Autoimmunity 2009;42:447-58. [DOI: 10.1080/08916930902911746] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
332 Stanczuk L, Martinez-corral I, Ulvmar MH, Zhang Y, Laviña B, Fruttiger M, Adams R, Saur D, Betsholtz C, Ortega S, Alitalo K, Graupera M, Mäkinen T. cKit Lineage Hemogenic Endothelium-Derived Cells Contribute to Mesenteric Lymphatic Vessels. Cell Reports 2015;10:1708-21. [DOI: 10.1016/j.celrep.2015.02.026] [Cited by in Crossref: 138] [Cited by in F6Publishing: 127] [Article Influence: 19.7] [Reference Citation Analysis]
333 Zheng W, Aspelund A, Alitalo K. Lymphangiogenic factors, mechanisms, and applications. J Clin Invest. 2014;124:878-887. [PMID: 24590272 DOI: 10.1172/jci71603] [Cited by in Crossref: 188] [Cited by in F6Publishing: 123] [Article Influence: 23.5] [Reference Citation Analysis]
334 Jun JE, Rubio I, Roose JP. Regulation of ras exchange factors and cellular localization of ras activation by lipid messengers in T cells. Front Immunol 2013;4:239. [PMID: 24027568 DOI: 10.3389/fimmu.2013.00239] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
335 Upadhyaya P, Qian Z, Selner NG, Clippinger SR, Wu Z, Briesewitz R, Pei D. Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. Angew Chem Int Ed Engl 2015;54:7602-6. [PMID: 25950772 DOI: 10.1002/anie.201502763] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 14.9] [Reference Citation Analysis]
336 Zhang M, Li Z, Wang G, Jang H, Sacks DB, Zhang J, Gaponenko V, Nussinov R. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α. J Phys Chem B 2018;122:11137-46. [PMID: 30047727 DOI: 10.1021/acs.jpcb.8b05982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
337 Patek CE, Arends MJ, Wallace WA, Luo F, Hagan S, Brownstein DG, Rose L, Devenney PS, Walker M, Plowman SJ, Berry RL, Kolch W, Sansom OJ, Harrison DJ, Hooper ML. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Experimental Cell Research 2008;314:1105-14. [DOI: 10.1016/j.yexcr.2007.11.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
338 Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-1083. [PMID: 20085938 DOI: 10.1200/jco.2009.25.3641] [Cited by in Crossref: 857] [Cited by in F6Publishing: 458] [Article Influence: 71.4] [Reference Citation Analysis]
339 Backer JM. The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol 2010;346:87-114. [PMID: 20544340 DOI: 10.1007/82_2010_52] [Cited by in Crossref: 23] [Cited by in F6Publishing: 45] [Article Influence: 2.1] [Reference Citation Analysis]
340 Bitterman PB, Polunovsky VA. Translational control of cell fate: from integration of environmental signals to breaching anticancer defense. Cell Cycle 2012;11:1097-107. [PMID: 22356766 DOI: 10.4161/cc.11.6.19610] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
341 von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts JH, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H. Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 2015;27:561-73. [PMID: 25843002 DOI: 10.1016/j.ccell.2015.02.014] [Cited by in Crossref: 122] [Cited by in F6Publishing: 108] [Article Influence: 17.4] [Reference Citation Analysis]
342 Sylvester DE, Chen Y, Grima N, Saletta F, Padhye B, Bennetts B, Wright D, Krivanek M, Graf N, Zhou L, Catchpoole D, Kirk J, Latchoumanin O, Qiao L, Ballinger M, Thomas D, Jamieson R, Dalla-Pozza L, Byrne JA. Rare germline variants in childhood cancer patients suspected of genetic predisposition to cancer. Genes Chromosomes Cancer 2021. [PMID: 34687117 DOI: 10.1002/gcc.23006] [Reference Citation Analysis]
343 Nardella C, Carracedo A, Salmena L, Pandolfi PP. Faithfull modeling of PTEN loss driven diseases in the mouse. Curr Top Microbiol Immunol 2010;347:135-68. [PMID: 20549475 DOI: 10.1007/82_2010_62] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
344 Sáinz-Jaspeado M, Claesson-Welsh L. Cytokines regulating lymphangiogenesis. Curr Opin Immunol 2018;53:58-63. [PMID: 29680577 DOI: 10.1016/j.coi.2018.04.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
345 Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol 2011;193:607-18. [PMID: 21576390 DOI: 10.1083/jcb.201012094] [Cited by in Crossref: 258] [Cited by in F6Publishing: 237] [Article Influence: 23.5] [Reference Citation Analysis]
346 Blasco RB, Francoz S, Santamaría D, Cañamero M, Dubus P, Charron J, Baccarini M, Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011;19:652-63. [PMID: 21514245 DOI: 10.1016/j.ccr.2011.04.002] [Cited by in Crossref: 193] [Cited by in F6Publishing: 182] [Article Influence: 17.5] [Reference Citation Analysis]
347 Liu Y, Su Y, Wang J, Sun S, Wang T, Qiao X, Run X, Li H, Liang Z. Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase. Neurochemistry International 2013;62:458-67. [DOI: 10.1016/j.neuint.2013.01.014] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
348 Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med. 2018;8. [PMID: 29229669 DOI: 10.1101/cshperspect.a031435] [Cited by in Crossref: 201] [Cited by in F6Publishing: 198] [Article Influence: 50.3] [Reference Citation Analysis]
349 Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T, Tremayne J, Ross LB, Pei Z, Friedman LS, Blackwood EM, Belvin M. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer Lett 2012;326:168-75. [PMID: 22902509 DOI: 10.1016/j.canlet.2012.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
350 Wu N, Huang Y, Liu F, Xu X, Liu B, Wei J. KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor. J Gastrointest Oncol 2021;12:1020-30. [PMID: 34295553 DOI: 10.21037/jgo-20-617] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Vicier C, Dieci MV, Andre F. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer. Curr Opin Oncol 2013;25:587-93. [PMID: 24097108 DOI: 10.1097/CCO.0000000000000014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
352 Krygowska AA, Castellano E. PI3K: A Crucial Piece in the RAS Signaling Puzzle. Cold Spring Harb Perspect Med 2018;8:a031450. [PMID: 28847905 DOI: 10.1101/cshperspect.a031450] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
353 Kaduwal S, Jeong WJ, Park JC, Lee KH, Lee YM, Jeon SH, Lim YB, Min do S, Choi KY. Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling. Oncotarget 2015;6:33091-105. [PMID: 26384305 DOI: 10.18632/oncotarget.5173] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
354 Murugan AK, Munirajan AK, Tsuchida N. Ras oncogenes in oral cancer: the past 20 years. Oral Oncol. 2012;48:383-392. [PMID: 22240207 DOI: 10.1016/j.oraloncology.2011.12.006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 7.8] [Reference Citation Analysis]
355 Gupta DK, Du J, Kamranvar SA, Johansson S. Tension-induced cytokinetic abscission in human fibroblasts. Oncotarget 2018;9:8999-9009. [PMID: 29507669 DOI: 10.18632/oncotarget.24016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
356 Cullis J, Meiri D, Sandi MJ, Radulovich N, Kent OA, Medrano M, Mokady D, Normand J, Larose J, Marcotte R, Marshall CB, Ikura M, Ketela T, Moffat J, Neel BG, Gingras AC, Tsao MS, Rottapel R. The RhoGEF GEF-H1 is required for oncogenic RAS signaling via KSR-1. Cancer Cell 2014;25:181-95. [PMID: 24525234 DOI: 10.1016/j.ccr.2014.01.025] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 7.5] [Reference Citation Analysis]
357 Restuccia DF, Hemmings BA. From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis Model Mech 2010;3:705-20. [PMID: 20940316 DOI: 10.1242/dmm.004671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
358 Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, Diefenbacher M, Stamp G, Downward J. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013;153:1050-63. [PMID: 23706742 DOI: 10.1016/j.cell.2013.04.031] [Cited by in Crossref: 184] [Cited by in F6Publishing: 172] [Article Influence: 20.4] [Reference Citation Analysis]
359 Martinez-Corral I, Zhang Y, Petkova M, Ortsäter H, Sjöberg S, Castillo SD, Brouillard P, Libbrecht L, Saur D, Graupera M, Alitalo K, Boon L, Vikkula M, Mäkinen T. Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation. Nat Commun 2020;11:2869. [PMID: 32513927 DOI: 10.1038/s41467-020-16496-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
360 Klinakis A, Szabolcs M, Chen G, Xuan S, Hibshoosh H, Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci USA. 2009;106:2359-2364. [PMID: 19174523 DOI: 10.1073/pnas.0810221106] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 5.4] [Reference Citation Analysis]
361 Yuan TL, McCormick F. Killing tumors by keeping ras and PI3' kinase apart. Cancer Cell 2013;24:562-3. [PMID: 24229705 DOI: 10.1016/j.ccr.2013.10.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
362 Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351-1356. [PMID: 19029981 DOI: 10.1038/nm.1890] [Cited by in Crossref: 987] [Cited by in F6Publishing: 889] [Article Influence: 70.5] [Reference Citation Analysis]
363 Malik NM, Gilroy DW, Kabouridis PS. Regulation of growth and survival of activated T cells by cell-transducing inhibitors of Ras. FEBS Lett 2009;583:61-9. [PMID: 19063885 DOI: 10.1016/j.febslet.2008.11.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
364 Poon HY, Stone JC. Functional links between diacylglycerol and phosphatidylinositol signaling systems in human leukocyte-derived cell lines. Biochem Biophys Res Commun 2009;390:1395-401. [PMID: 19896467 DOI: 10.1016/j.bbrc.2009.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
365 Saji M, Ringel MD. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 2010;321:20-28. [PMID: 19897009 DOI: 10.1016/j.mce.2009.10.016] [Cited by in Crossref: 112] [Cited by in F6Publishing: 110] [Article Influence: 8.6] [Reference Citation Analysis]
366 Boulbes D, Chen CH, Shaikenov T, Agarwal NK, Peterson TR, Addona TA, Keshishian H, Carr SA, Magnuson MA, Sabatini DM, Sarbassov dos D. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res 2010;8:896-906. [PMID: 20501647 DOI: 10.1158/1541-7786.MCR-09-0409] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
367 Ferguson SM. Membrane traffic en route to cancer. Science 2015;350:162-3. [DOI: 10.1126/science.aad3575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
368 Cho DC. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook. BioDrugs 2014;28:373-81. [PMID: 24567265 DOI: 10.1007/s40259-014-0090-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
369 Kumar M, Hancock D, Molina-arcas M, Steckel M, East P, Diefenbacher M, Armenteros-monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J. The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer. Cell 2012;149:642-55. [DOI: 10.1016/j.cell.2012.02.059] [Cited by in Crossref: 195] [Cited by in F6Publishing: 191] [Article Influence: 19.5] [Reference Citation Analysis]
370 Mori M, Mori T, Yamamoto A, Takagi S, Ueda M. Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression. Hum Cell 2019;32:367-78. [PMID: 30963412 DOI: 10.1007/s13577-019-00249-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
371 Mclean BA, Zhabyeyev P, Pituskin E, Paterson I, Haykowsky MJ, Oudit GY. PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine. Journal of Cardiac Failure 2013;19:268-82. [DOI: 10.1016/j.cardfail.2013.02.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
372 Fujioka Y, Tsuda M, Hattori T, Sasaki J, Sasaki T, Miyazaki T, Ohba Y. The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses. PLoS One 2011;6:e16324. [PMID: 21283725 DOI: 10.1371/journal.pone.0016324] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
373 Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov 2014;4:1182-97. [PMID: 25100204 DOI: 10.1158/2159-8290.CD-13-0900] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
374 Tanaka T, Rabbitts TH. Interfering with RAS–effector protein interactions prevent RAS-dependent tumour initiation and causes stop–start control of cancer growth. Oncogene 2010;29:6064-70. [DOI: 10.1038/onc.2010.346] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
375 Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, Larson SM, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol 2017;13:914. [PMID: 28202506 DOI: 10.15252/msb.20167159] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
376 Pawson T, Nash P. Modular Protein Interaction Domains in Cellular Communication. Handbook of Cell Signaling. Elsevier; 2010. pp. 399-411. [DOI: 10.1016/b978-0-12-374145-5.00057-7] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
377 Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res 2013;73:6448-61. [PMID: 24019382 DOI: 10.1158/0008-5472.CAN-13-0681] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
378 Marqués M, Kumar A, Cortés I, Gonzalez-García A, Hernández C, Moreno-Ortiz MC, Carrera AC. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol. 2008;28:2803-2814. [PMID: 18285463 DOI: 10.1128/MCB.01786-07] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
379 Lee J, Jain A, Kim P, Lee T, Kuller A, Princen F, In-GuDo, Kim SH, Park JO, Park YS, Singh S, Kim HC. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. PLoS One 2014;9:e103551. [PMID: 25090459 DOI: 10.1371/journal.pone.0103551] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
380 Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 2010;107:11381-6. [PMID: 20534549 DOI: 10.1073/pnas.0906461107] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 9.4] [Reference Citation Analysis]
381 Zhao L, Vogt PK. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 2010;9:596-600. [PMID: 20009532 DOI: 10.4161/cc.9.3.10599] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 6.3] [Reference Citation Analysis]
382 Sims D, Duchek P, Baum B. PDGF/VEGF signaling controls cell size in Drosophila. Genome Biol 2009;10:R20. [PMID: 19216764 DOI: 10.1186/gb-2009-10-2-r20] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
383 Bell CM, Raffeiner P, Hart JR, Vogt PK. PIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9. Cancers (Basel) 2019;11:E1634. [PMID: 31652979 DOI: 10.3390/cancers11111634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
384 Wang Q, Tao C, Hannan A, Yoon S, Min X, Peregrin J, Qu X, Li H, Yu H, Zhao J, Zhang X. Lacrimal gland budding requires PI3K-dependent suppression of EGF signaling. Sci Adv 2021;7:eabf1068. [PMID: 34193412 DOI: 10.1126/sciadv.abf1068] [Reference Citation Analysis]
385 Vasjari L, Bresan S, Biskup C, Pai G, Rubio I. Ras signals principally via Erk in G1 but cooperates with PI3K/Akt for Cyclin D induction and S-phase entry. Cell Cycle 2019;18:204-25. [PMID: 30560710 DOI: 10.1080/15384101.2018.1560205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
386 Agollah GD, Gonzalez-Garay ML, Rasmussen JC, Tan IC, Aldrich MB, Darne C, Fife CE, Guilliod R, Maus EA, King PD, Sevick-Muraca EM. Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction. PLoS One 2014;9:e112548. [PMID: 25383712 DOI: 10.1371/journal.pone.0112548] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
387 Choudhury AR, Singh KK. Mitochondrial determinants of cancer health disparities. Semin Cancer Biol 2017;47:125-46. [PMID: 28487205 DOI: 10.1016/j.semcancer.2017.05.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
388 Fan HY, Shimada M, Liu Z, Cahill N, Noma N, Wu Y, Gossen J, Richards JS. Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation. Development 2008;135:2127-37. [PMID: 18506027 DOI: 10.1242/dev.020560] [Cited by in Crossref: 103] [Cited by in F6Publishing: 105] [Article Influence: 7.4] [Reference Citation Analysis]
389 Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3:1787-1808. [PMID: 22004085 DOI: 10.4155/fmc.11.121] [Cited by in Crossref: 266] [Cited by in F6Publishing: 247] [Article Influence: 26.6] [Reference Citation Analysis]
390 Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10:842-857. [PMID: 21102635 DOI: 10.1038/nrc2960] [Cited by in Crossref: 486] [Cited by in F6Publishing: 454] [Article Influence: 40.5] [Reference Citation Analysis]
391 Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A 2008;105:2652-7. [PMID: 18268322 DOI: 10.1073/pnas.0712169105] [Cited by in Crossref: 285] [Cited by in F6Publishing: 280] [Article Influence: 20.4] [Reference Citation Analysis]
392 Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J. 2008;415:333-344. [PMID: 18842113 DOI: 10.1042/BJ20081056] [Cited by in Crossref: 249] [Cited by in F6Publishing: 137] [Article Influence: 17.8] [Reference Citation Analysis]
393 Le Floc'h A, Huse M. Molecular mechanisms and functional implications of polarized actin remodeling at the T cell immunological synapse. Cell Mol Life Sci 2015;72:537-56. [PMID: 25355055 DOI: 10.1007/s00018-014-1760-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
394 Carnero A. Novel inhibitors of the PI3K family. Expert Opinion on Investigational Drugs 2009;18:1265-77. [DOI: 10.1517/13543780903066798] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
395 Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Curr Opin Urol 2016;26:231-9. [PMID: 26909474 DOI: 10.1097/MOU.0000000000000278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
396 Ghomlaghi M, Hart A, Hoang N, Shin S, Nguyen LK. Feedback, Crosstalk and Competition: Ingredients for Emergent Non-Linear Behaviour in the PI3K/mTOR Signalling Network. Int J Mol Sci 2021;22:6944. [PMID: 34203293 DOI: 10.3390/ijms22136944] [Reference Citation Analysis]
397 Bigenzahn JW, Fauster A, Rebsamen M, Kandasamy RK, Scorzoni S, Vladimer GI, Müller AC, Gstaiger M, Zuber J, Bennett KL, Superti-Furga G. An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Mol Cell Proteomics 2016;15:1139-50. [PMID: 26933192 DOI: 10.1074/mcp.o115.055350] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
398 Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011;141:50-61. [PMID: 21723986 DOI: 10.1053/j.gastro.2011.05.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
399 Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol 2017;407:153-89. [PMID: 28550454 DOI: 10.1007/82_2017_6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 70] [Article Influence: 10.7] [Reference Citation Analysis]
400 Downward J. Targeting RAS and PI3K in lung cancer. Nat Med 2008;14:1315-6. [PMID: 19057554 DOI: 10.1038/nm1208-1315] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]